Advertisement

Topics

Alnylam review turns up no clear answers on revusiran deaths

05:53 EDT 10 Aug 2017 | BioPharmaDive

A higher number of patient deaths in the treatment arm of a Phase 3 study had led Alnylam last year to abandon revusiran, then its lead program. 

Original Article: Alnylam review turns up no clear answers on revusiran deaths

NEXT ARTICLE

More From BioPortfolio on "Alnylam review turns up no clear answers on revusiran deaths"

Quick Search
Advertisement